Rafarma Pharmaceuticals Inc (RAFA) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Rafarma Pharmaceuticals Inc $0.08, price $0.04, upside +95.3%, quality 54 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Rafarma Pharmaceuticals Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range $0.0169 – $1.88 · fair‑value band $0.0509 – $0.0936 · the $0.0400 price screens below the $0.0781 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.
Follow Rafarma Pharmaceuticals in your weekly email
Every Wednesday you see whether Rafarma Pharmaceuticals is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Rafarma Pharmaceuticals, Inc., a multi-product pharmaceutical company, produces and sells drugs, generic antibiotics, and specialty pharmaceuticals in Russia. It offers cephalosporin-based products, antibiotics of non-ß structure, and anti-cancer drugs in the form of injections, ampulla packaged products, child suspensions, tablets, and capsules.
Show more
Rafarma Pharmaceuticals, Inc., a multi-product pharmaceutical company, produces and sells drugs, generic antibiotics, and specialty pharmaceuticals in Russia. It offers cephalosporin-based products, antibiotics of non-ß structure, and anti-cancer drugs in the form of injections, ampulla packaged products, child suspensions, tablets, and capsules. The company also provides drugs for accidental wounds, inflammatory eye diseases, and immunological disorders. The company has a collaboration agreement with PlantEXT Ltd. to research and manufacture the first medical cannabis suppositories for patients suffering from inflammatory bowel disease. Rafarma Pharmaceuticals, Inc. was formerly known as Johnston Acquisition Corp. and changed its name to Rafarma Pharmaceuticals, Inc. in October 2012. The company is based in Sandy, Utah with a manufacturing and distribution facility in Russia. As of October 19, 2020, Rafarma Pharmaceuticals, Inc. operates as a subsidiary of R. & D. Biocogency Laboratories Inc. Ltd.
Stock analysis
Rafarma Pharmaceuticals Inc (RAFA) currently trades at $0.0400, while our model-based Fair Value estimate is $0.0781, implying the stock looks roughly 48.8% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of $0.2600 per share, and 15 of the 15 models we run sit above the $0.0400 price.
Bear case: the Economic Profit group reads lowest at $0.0500, and 0 of the 15 models stay below the price. Evidence for this calculation is low.
Scenario range: $0.0509 (bear) to $0.0936 (bull), the price of $0.0400 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 54/100 (solid quality), in the Healthcare sector.
Mixed Growth: Spin-off in 2024: revenue and profit before it include the divested business. Growth is measured afresh from 2024.
Rafarma Pharmaceuticals Inc reported revenue of $9.2M in FY2025 versus $77.4M in FY2021, a compound −41.3%/yr. Reported net income was $349K in FY2025, compounding −58.3%/yr from FY2021.
Key figures
Market cap $4.1M · P/S ratio 30.9 · EPS (TTM) $−0.0140 · Net margin 3.8% · Return on equity −0.1% · Return on assets (EBIT) 6.8% · Operating margin −81.3% · Free cash flow −$16.0K.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).
What moves the price
The share trades about 55% below its 52-week high and 137% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at 95%, RAFA screens cheaper than that median.
Fair Value models
Bear $0.0509Fair Value $0.0781Bull $0.0936
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.55/100
Spin-off in 2024: revenue and profit before it include the divested business. Growth is measured afresh from 2024.
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−50.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year−50.4%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.26% → 5%
Compare Rafarma Pharmaceuticals Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 628 stocks
Beats the industry median on 4/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score54 · Above median
Fair Value upside+95% · Top 25%
Profitability
Return on assets0% · Below median
Net margin (TTM)−88% · Bottom 25%
Operating margin (TTM)−81% · Bottom 25%
Growth and dividend
Revenue growth0% · Below median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Rafarma Pharmaceuticals Inc (RAFA) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $0.0781 versus a price of $0.0400, about +95% upside (undervalued).
What is the fair value of RAFA?
Our model-based fair value for Rafarma Pharmaceuticals Inc is $0.0781 (as of Sep 23, 2026), built from audited fundamentals. The current price: $0.0400.
What is the quality score of RAFA?
Rafarma Pharmaceuticals Inc has a Quality Score of 54/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Rafarma Pharmaceuticals Inc (RAFA)?
Our model-based price target is the fair value of $0.0781 (as of Sep 23, 2026) from 15 valuation models. Cautious scenario $0.0509, optimistic scenario $0.0936. It is a calculation from audited fundamentals, not an analyst target.
What is the Rafarma Pharmaceuticals Inc stock forecast for 2026?
Our models put fair value at $0.0781, about +95% upside versus a price of $0.0400 (undervalued). Cautious scenario $0.0509, optimistic scenario $0.0936. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Rafarma Pharmaceuticals Inc (RAFA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Rafarma Pharmaceuticals Inc it is $0.0781 per share (as of Sep 23, 2026), against a price of $0.0400. It is the blended result of 15 valuation models (cash flow, earnings, asset, dividend).
Is Rafarma Pharmaceuticals Inc stock overvalued or undervalued in 2026?
As of Sep 23, 2026, RAFA trades below its calculated fair value: price $0.0400, fair value $0.0781, a gap of about +95% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of RAFA?
No. The price is what the market pays today ($0.0400); the fair value is what the company's own numbers justify ($0.0781). For Rafarma Pharmaceuticals Inc the two are $0.0381 per share apart. That gap is exactly why we show both numbers side by side.
How much is Rafarma Pharmaceuticals Inc worth?
The market values Rafarma Pharmaceuticals Inc at about $4.1M (market capitalisation, as of Sep 23, 2026). Per share that is $0.0400; our models calculate a fair value of $0.0781 per share.
What do the bullish and bearish scenarios say about RAFA?
Our models span a range for Rafarma Pharmaceuticals Inc: cautious scenario $0.0509, base $0.0781, optimistic $0.0936 per share (as of Sep 23, 2026, price $0.0400). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Rafarma Pharmaceuticals Inc (RAFA)?
Balance-sheet figures for Rafarma Pharmaceuticals Inc (as of Sep 23, 2026): return on equity −0.1%. They feed the Quality Score of 54/100, which measures business quality independently of the share price.
How far is RAFA from its 52-week high?
Rafarma Pharmaceuticals Inc trades at $0.0400, about 55% below its 52-week high of $0.0890 and 137% above the low of $0.0169 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0781 is for.
Which stocks are comparable to Rafarma Pharmaceuticals Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Rafarma Pharmaceuticals Inc stock attractive at the current price?
The data as of Sep 23, 2026: price $0.0400, calculated fair value $0.0781 (+95%), Quality Score 54/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of RAFA calculated?
We run Rafarma Pharmaceuticals Inc through 15 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0781, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Rafarma Pharmaceuticals Inc currently trades 95 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Rafarma Pharmaceuticals Inc (RAFA)?
The closing price on Sep 23, 2026 was $0.0400. Our model-based fair value is $0.0781, about +95% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Rafarma Pharmaceuticals Inc right now?
The price is below even our cautious bear case ($0.0509). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (54/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range ($0.0509 to $0.0936) leaves room in how you read the outcome.
Key figures of Rafarma Pharmaceuticals Inc
How large is the market capitalisation of Rafarma Pharmaceuticals Inc (RAFA)?
The market capitalisation of Rafarma Pharmaceuticals Inc is $4.1M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Rafarma Pharmaceuticals Inc (RAFA)?
The price-to-sales ratio of Rafarma Pharmaceuticals Inc is 30.9 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Rafarma Pharmaceuticals Inc (RAFA)?
Earnings per share at Rafarma Pharmaceuticals Inc are $−0.0140. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Rafarma Pharmaceuticals Inc (RAFA)?
The net margin of Rafarma Pharmaceuticals Inc is 3.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Rafarma Pharmaceuticals Inc (RAFA)?
The return on equity (ROE) of Rafarma Pharmaceuticals Inc is −0.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Rafarma Pharmaceuticals Inc (RAFA)?
On an EBIT basis the return on assets of Rafarma Pharmaceuticals Inc is 6.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Rafarma Pharmaceuticals Inc (RAFA)?
The operating margin of Rafarma Pharmaceuticals Inc is −81.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much free cash flow does Rafarma Pharmaceuticals Inc (RAFA) generate?
The free cash flow of Rafarma Pharmaceuticals Inc is −$16.0K (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Rafarma Pharmaceuticals Inc (RAFA) hold?
Rafarma Pharmaceuticals Inc holds more cash than debt, $35.0K net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Rafarma Pharmaceuticals Inc in the live analysis
One click puts Rafarma Pharmaceuticals Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 23, 2026